Mechanism of action
Cyclobenzaprine acts centrally within the brainstem, primarily at the level of the reticular formation and spinal cord. It reduces tonic somatic motor activity influencing both alpha and gamma motor neurons. Unlike neuromuscular blocking agents, cyclobenzaprine does not act directly on skeletal muscle, the neuromuscular junction, or muscle spindles.
The drug's mechanism involves reduction of muscle spasm through decreased motor neuron activity without interfering with muscle function. It is structurally similar to tricyclic antidepressants, sharing a tricyclic chemical structure that explains many of its side effects. Cyclobenzaprine may modulate noradrenergic pathways in the descending motor control system.
Key distinction: Cyclobenzaprine is not a peripheral muscle relaxant and does not produce neuromuscular blockade. Its primary site of action is the central nervous system, not the muscle itself. The muscle relaxation observed is secondary to reduced central motor output.
- Cyclobenzaprine is structurally related to tricyclic antidepressants and shares their anticholinergic and sedative effects
- Acts centrally in the brainstem, not at the neuromuscular junction or on muscle tissue directly
- Absolutely contraindicated with MAOIs (14-day washout required) due to risk of hypertensive crisis
- Beers Criteria: potentially inappropriate for elderly due to anticholinergic effects, sedation, and fall risk
- Contraindicated in acute MI recovery phase, arrhythmias, heart failure, and hyperthyroidism
- Intended for short-term use only (2-3 weeks); not effective for spasticity from CNS disorders
- Can contribute to serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic drugs
- Most common side effects are drowsiness (up to 40%) and dry mouth due to anticholinergic activity
Indications
Cyclobenzaprine is indicated for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is intended as an adjunct to rest, physical therapy, and other measures for the symptomatic treatment of acute musculoskeletal pain.
Approved uses
- Acute musculoskeletal pain with muscle spasm (back pain, neck pain, sprains, strains)
- Short-term management (2-3 weeks duration)
- Adjunct to rest and physical therapy
Important limitations
Cyclobenzaprine is not effective for muscle spasm due to central nervous system diseases such as cerebral palsy or spinal cord injury. It is intended only for acute musculoskeletal conditions, not chronic pain syndromes. Effectiveness beyond 2-3 weeks has not been established, and prolonged use is not recommended.
Off-label: Sometimes used for fibromyalgia at low doses, though this is not an FDA-approved indication.
Pharmacokinetics
Cyclobenzaprine exhibits well-characterized pharmacokinetics that influence its clinical use and dosing considerations.
Absorption: Well absorbed orally with onset of action within 1 hour. Peak plasma concentrations occur 3-8 hours after administration. Food does not significantly affect absorption.
Distribution: Highly protein-bound (93%). Widely distributed throughout the body with a large volume of distribution.
Metabolism: Extensively metabolized by the liver via CYP3A4, CYP1A2, and CYP2D6 pathways. Undergoes enterohepatic recycling, which contributes to its prolonged half-life. Active metabolites are formed but contribute minimally to clinical effects.
Elimination: Elimination half-life is 18 hours (range 8-37 hours), allowing for sustained effects. Excreted primarily via the kidneys as conjugated metabolites. Less than 1% is excreted unchanged in urine.
Special populations: Hepatic impairment significantly prolongs half-life and increases exposure. Elderly patients experience reduced clearance and increased sensitivity to effects. Dosage adjustment follows product labeling for hepatic dysfunction.
Adverse effects
Cyclobenzaprine's adverse effect profile closely resembles that of tricyclic antidepressants due to structural similarity. The most common and clinically significant effects relate to anticholinergic and sedative properties.
Common adverse effects (>10%)
- Drowsiness and sedation (most common, up to 40%)
- Dry mouth (xerostomia)
- Dizziness and lightheadedness
- Fatigue and weakness
Frequent adverse effects (1-10%)
- Headache
- Confusion (especially in elderly)
- Constipation
- Nausea and dyspepsia
- Blurred vision
- Unpleasant taste
- Nervousness
Serious adverse effects
- Cardiac arrhythmias: Risk of QT prolongation, tachycardia, palpitations
- Anticholinergic crisis: Severe anticholinergic syndrome with confusion, urinary retention, hyperthermia
- Serotonin syndrome (when combined with serotonergic drugs)
- Seizures (rare, usually in predisposed individuals)
Anticholinergic effects
Cyclobenzaprine exhibits significant anticholinergic activity leading to dry mouth, urinary retention, constipation, blurred vision, increased intraocular pressure, and cognitive impairment. These effects are particularly problematic in elderly patients and contribute to its inclusion on the Beers Criteria list of potentially inappropriate medications for older adults.
Exam tip: The anticholinergic burden mimics atropine-like effects and can precipitate acute angle-closure glaucoma or urinary retention in susceptible patients.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to cyclobenzaprine
- Acute recovery phase of myocardial infarction
- Arrhythmias (heart block, conduction disturbances)
- Heart failure
- Hyperthyroidism
- Concomitant or recent (within 14 days) MAOI use
Relative contraindications and warnings
- Elderly patients: Beers Criteria lists cyclobenzaprine as potentially inappropriate due to anticholinergic effects, sedation, and increased fracture risk
- Hepatic impairment (contraindicated in moderate to severe)
- Closed-angle glaucoma or increased intraocular pressure
- Urinary retention or prostatic hypertrophy
- Cognitive impairment or dementia
- History of seizures
Black box warnings
Cyclobenzaprine does not carry a black box warning.
Pregnancy and lactation
Pregnancy category B: Animal studies show no fetal risk, but human data are limited. Use only if clearly needed.
Lactation: Unknown whether cyclobenzaprine is excreted in breast milk. Use caution in nursing mothers due to potential for sedation and anticholinergic effects in infants.
Special precautions
Patients should be warned about sedation and advised not to drive or operate machinery until effects are known. Alcohol and other CNS depressants potentiate sedation. The risk of falls is significantly increased, especially in elderly patients.
Drug interactions
Cyclobenzaprine participates in multiple clinically significant drug interactions, primarily involving CNS depression, anticholinergic effects, and serotonergic activity.
Major interactions
MAO inhibitors: Absolute contraindication. Combined use can precipitate hypertensive crisis, hyperpyrexia, seizures, and death. Allow 14-day washout after MAOI discontinuation before starting cyclobenzaprine.
Serotonergic drugs: Risk of serotonin syndrome when combined with SSRIs, SNRIs, tramadol, triptans, linezolid, or St. John's wort. Monitor for agitation, hyperthermia, hyperreflexia, and autonomic instability.
CNS depressants: Additive sedation with benzodiazepines, opioids, alcohol, antihistamines, barbiturates, and other sedatives. Increased risk of respiratory depression and falls.
Moderate interactions
Anticholinergic drugs: Additive anticholinergic burden with antihistamines, antipsychotics, tricyclic antidepressants, and bladder antimuscarinics. Risk of confusion, urinary retention, constipation, and cognitive impairment.
CYP metabolism: CYP3A4 inhibitors (ketoconazole, erythromycin, grapefruit juice) may increase cyclobenzaprine levels. CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce efficacy.
Drug-disease interactions
Cardiac disease, glaucoma, urinary retention, and hepatic impairment represent critical drug-disease interactions requiring avoidance or extreme caution.
Exam pearl: The MAOI interaction is a classic board question scenario. Remember the 14-day washout period.
Clinical pearls
- Structurally related to TCAs: Cyclobenzaprine shares the tricyclic structure and many adverse effects with amitriptyline and other tricyclic antidepressants, but lacks significant antidepressant activity at muscle relaxant doses.
- No direct muscle action: Unlike dantrolene or neuromuscular blockers, cyclobenzaprine works centrally in the brainstem—it does not act on muscle tissue itself. This is a high-yield board concept.
- Beers Criteria medication: Inappropriate for elderly patients due to anticholinergic effects and sedation. Falls, confusion, and urinary retention are particular concerns in this population.
- Short-term use only: Efficacy beyond 2-3 weeks is not established. Cyclobenzaprine is intended for acute musculoskeletal conditions, not chronic pain management.
- Not controlled: Unlike carisoprodol (Schedule IV), cyclobenzaprine is not a controlled substance, though it can cause sedation and has abuse potential in some individuals.
- MAOI interaction is classic: The combination can be fatal. This is a high-yield question stem on boards involving a patient on phenelzine or tranylcypromine presenting with muscle spasm.
- Limited benefit over placebo: Meta-analyses show modest improvement in muscle spasm over placebo (effect size around 0.4), with significant sedation limiting utility. Many patients discontinue due to side effects.
- Serotonin syndrome risk: Though not an SSRI, cyclobenzaprine has serotonergic activity and can contribute to serotonin syndrome when combined with other serotonergic agents.
- Cardiac caution: Avoid in recent MI, arrhythmias, and heart failure due to tricyclic-like cardiac effects including conduction delays and arrhythmia risk.
- Consider alternatives in elderly: Tizanidine or physical therapy alone may be safer alternatives in older adults given cyclobenzaprine's anticholinergic burden.
Cyclobenzaprine = "TRICYCLIC Muscle drug": Think TCA (Tricyclic structure), Remember Inapplicability in Cardiac disease, CNS action (not muscle), Contraindicated with MAOIs, Long half-life, Inappropriate for elderly, Causes anticholinergic effects
Practice questions
1. A 72-year-old man with benign prostatic hyperplasia presents to the emergency department with confusion, urinary retention, dilated pupils, dry flushed skin, and hyperthermia. His wife reports he started taking a new medication for back pain 3 days ago. Vital signs: temperature 39.2°C, heart rate 118/min, blood pressure 158/92 mmHg. Which medication most likely caused this presentation?
2. A 45-year-old woman with major depressive disorder treated with phenelzine presents with acute low back pain after lifting heavy boxes. Physical examination reveals paraspinal muscle tenderness and spasm without neurological deficits. Which of the following medications should be avoided in this patient?
3. A 55-year-old man is prescribed cyclobenzaprine for acute neck pain following a motor vehicle collision. He asks whether the medication will help with muscle spasms in his legs from his multiple sclerosis. What is the most appropriate response?
Frequently asked questions
How does cyclobenzaprine work?
Cyclobenzaprine works centrally in the brainstem by reducing tonic somatic motor activity that influences both alpha and gamma motor neurons. Unlike neuromuscular blockers, it does not act directly on skeletal muscle or the neuromuscular junction. Instead, it decreases muscle spasm by reducing motor neuron activity in the central nervous system, particularly at the reticular formation and spinal cord level. Its mechanism is thought to involve modulation of descending noradrenergic pathways, and it is structurally similar to tricyclic antidepressants.
What are the side effects of cyclobenzaprine?
The most common side effects are drowsiness (affecting up to 40% of patients) and dry mouth due to anticholinergic activity. Other frequent effects include dizziness, fatigue, confusion (especially in elderly), constipation, blurred vision, and headache. Serious adverse effects include cardiac arrhythmias, anticholinergic crisis, serotonin syndrome when combined with other serotonergic drugs, and rarely seizures. The anticholinergic effects can cause urinary retention, increased intraocular pressure, and cognitive impairment, making it particularly problematic for elderly patients.
Is cyclobenzaprine a controlled substance?
No, cyclobenzaprine is not a controlled substance under the DEA scheduling system. Unlike carisoprodol (Soma), which is Schedule IV due to its metabolite meprobamate, cyclobenzaprine has no DEA schedule classification. However, it does cause significant sedation and has some potential for misuse, particularly when combined with other CNS depressants. Despite not being controlled, prescribers should still exercise caution and limit prescriptions to short-term use (2-3 weeks) for acute musculoskeletal conditions only.
Cyclobenzaprine vs tizanidine — what is the difference?
Both are centrally acting muscle relaxants for acute musculoskeletal pain, but they differ significantly. Cyclobenzaprine is structurally related to tricyclic antidepressants and has prominent anticholinergic and sedative effects, making it inappropriate for elderly patients. Tizanidine is an alpha-2 adrenergic agonist with less anticholinergic activity but causes hypotension and has significant hepatotoxicity risk requiring liver monitoring. Tizanidine may be preferred in elderly patients or those with cardiac contraindications to cyclobenzaprine, though both drugs have substantial sedation and limited evidence for superior efficacy over placebo.
Can you take cyclobenzaprine with antidepressants?
Caution is required when combining cyclobenzaprine with antidepressants. It is absolutely contraindicated with MAO inhibitors due to risk of hypertensive crisis, seizures, and death; a 14-day washout is required after stopping an MAOI. With SSRIs and SNRIs, there is risk of serotonin syndrome due to cyclobenzaprine's serotonergic activity—monitor for agitation, confusion, hyperthermia, and muscle rigidity. With tricyclic antidepressants, there is additive anticholinergic burden increasing risks of urinary retention, confusion, and cardiac effects. If combination therapy is necessary, use the lowest effective doses and monitor closely.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: M03BX08
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.